Potential therapeutic use of PPARγ-programed human monocyte-derived dendritic cells in cancer vaccination therapy

2Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Dendritic cells (DCs) can regulate all elements of the immune system, and therefore are an ideal target for vaccination. During the last two decades, as a result of extensive research, DCs became the primary target of antitumor vaccination as well. A critical issue of antitumor vaccination is the phenotype of the dendritic cell used. It has been recently shown that several nuclear hormone receptors, and amongst them the lipid-activated nuclear receptor and peroxisome proliferator-activated receptor gamma (PPAR γ), have important roles in effecting the immunophenotype of human dendritic cells. It regulates primarily lipid metabolism and via this it influences the immunophenotype of DCs by altering lipid antigen uptake, presentation, and also other immune functions. In this review, we summarize the principles of antitumor vaccination strategies and present our hypothesis on how PPAR γ -regulated processes might be involved and could be exploited in the design of vaccination strategies. Copyright © 2008 A. Gyöngyösi and L. Nagy.

Cite

CITATION STYLE

APA

Gyöngyösi, A., & Nagy, L. (2008). Potential therapeutic use of PPARγ-programed human monocyte-derived dendritic cells in cancer vaccination therapy. PPAR Research. https://doi.org/10.1155/2008/473804

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free